{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,24]],"date-time":"2025-12-24T12:42:06Z","timestamp":1766580126756},"reference-count":56,"publisher":"The Endocrine Society","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2000,1,1]]},"abstract":"<jats:p>Recent data suggest an interaction between the renin-angiotensin-aldosterone system and fibrinolysis. Although previous work has focused on the effect of angiotensin II (Ang II) on plasminogen activator inhibitor (PAI-1) expression, the present study tests the hypothesis that aldosterone contributes to the regulation of PAI-1 expression. To test this hypothesis in vitro, luciferase reporter constructs containing the human PAI-1 promoter were transfected into rat aortic smooth muscle cells. Exposure of the cells to 100 nmol\/L Ang II resulted in a 3-fold increase in luciferase activity. Neither 1 \u03bcmol\/L dexamethasone nor 1 \u03bcmol\/L aldosterone alone increased PAI-1 expression. However, both dexamethasone and aldosterone enhanced the effect of Ang II in a dose-dependent manner. This effect was abolished by mutation in the region of a putative glucocorticoid-responsive element. A similar interactive effect of Ang II and aldosterone was observed in cultured human umbilical vein endothelial cells. The time course of the effect of aldosterone on Ang II-induced PAI-1 expression was consistent with a classical mineralocorticoid receptor mechanism, and the effect of aldosterone on PAI-1 synthesis was attenuated by spironolactone. To determine whether aldosterone affected PAI-1 expression in vivo, we measured local venous PAI-1 antigen concentrations in six patients with primary hyperaldosteronism undergoing selective adrenal vein sampling. PAI-1 antigen, but not tissue plasminogen activator antigen, concentrations were significantly higher in adrenal venous blood than in peripheral venous blood. Taken together, these data support the hypothesis that aldosterone modulates the effect of Ang II on PAI-1 expression in vitro and in vivo in humans.<\/jats:p>","DOI":"10.1210\/jcem.85.1.6305","type":"journal-article","created":{"date-parts":[[2014,1,8]],"date-time":"2014-01-08T17:05:28Z","timestamp":1389200728000},"page":"336-344","source":"Crossref","is-referenced-by-count":10,"title":["Synergistic Effect of Adrenal Steroids and Angiotensin II on Plasminogen Activator Inhibitor-1 Production1"],"prefix":"10.1210","volume":"85","author":[{"given":"Nancy J.","family":"Brown","sequence":"first","affiliation":[{"name":"Departments of Medicine (N.J.B., K.-S.K., L.S.B., J.H.N., D.E.V.), Nashville, Tennessee 37212"},{"name":"Pharmacology (N.J.B., K.-S.K., Y.-Q.C., D.E.V.), Nashville, Tennessee 37212"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kyung-Soo","family":"Kim","sequence":"additional","affiliation":[{"name":"Departments of Medicine (N.J.B., K.-S.K., L.S.B., J.H.N., D.E.V.), Nashville, Tennessee 37212"},{"name":"Pharmacology (N.J.B., K.-S.K., Y.-Q.C., D.E.V.), Nashville, Tennessee 37212"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan-Qun","family":"Chen","sequence":"additional","affiliation":[{"name":"Pharmacology (N.J.B., K.-S.K., Y.-Q.C., D.E.V.), Nashville, Tennessee 37212"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lewis S.","family":"Blevins","sequence":"additional","affiliation":[{"name":"Departments of Medicine (N.J.B., K.-S.K., L.S.B., J.H.N., D.E.V.), Nashville, Tennessee 37212"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John H.","family":"Nadeau","sequence":"additional","affiliation":[{"name":"Departments of Medicine (N.J.B., K.-S.K., L.S.B., J.H.N., D.E.V.), Nashville, Tennessee 37212"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steven G.","family":"Meranze","sequence":"additional","affiliation":[{"name":"Radiology (S.G.M.), Vanderbilt University Medical Center, Nashville, Tennessee 37232; and Veterans Administration Medical Center, Nashville, Tennessee 37212"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Douglas E.","family":"Vaughan","sequence":"additional","affiliation":[{"name":"Departments of Medicine (N.J.B., K.-S.K., L.S.B., J.H.N., D.E.V.), Nashville, Tennessee 37212"},{"name":"Pharmacology (N.J.B., K.-S.K., Y.-Q.C., D.E.V.), Nashville, Tennessee 37212"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"80","reference":[{"key":"2020071619403596600_R1","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1056\/NEJM197203022860901","article-title":"Essential hypertension: renin and aldosterone, heart attack and stroke.","volume":"286","author":"Brunner","year":"1972","journal-title":"N Engl J Med"},{"key":"2020071619403596600_R2","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1056\/NEJM199104183241605","article-title":"Association of the renin-sodium profile with the risk of myocardial infarction in patients with hypertension.","volume":"324","author":"Alderman","year":"1991","journal-title":"N Engl J Med"},{"key":"2020071619403596600_R3","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1056\/NEJM199209033271001","article-title":"Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction.","volume":"327","author":"Pfeffer","year":"1992","journal-title":"N Engl J Med"},{"key":"2020071619403596600_R4","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1016\/0140-6736(92)92889-N","article-title":"Effect of enalapril on myocardial infarction and unstable angina in patients with low ejection fractions.","volume":"340","author":"Yusuf","year":"1992","journal-title":"Lancet"},{"key":"2020071619403596600_R5","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1172\/JCI117809","article-title":"Angiotensin II regulates the expression of plasminogen activator inhibitor-1 in cultured endothelial cells.","volume":"95","author":"Vaughan","year":"1995","journal-title":"J Clin Invest"},{"key":"2020071619403596600_R6","doi-asserted-by":"crossref","first-page":"2515","DOI":"10.1172\/JCI118312","article-title":"Angiotensin induction of PAI-1 expression in endothelial cells is mediated by the hexapeptide angiotensin IV.","volume":"96","author":"Kerins","year":"1995","journal-title":"J Clin Invest"},{"key":"2020071619403596600_R7","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1146\/annurev.cb.04.110188.000521","article-title":"Cell-associated plasminogen activation: regulation and physiologic functions.","volume":"4","author":"Saksela","year":"1988","journal-title":"Annu Rev Cell Biol"},{"key":"2020071619403596600_R8","doi-asserted-by":"crossref","first-page":"6998","DOI":"10.1073\/pnas.89.15.6998","article-title":"Increased type 1 plasminogen activator inhibitor gene expression in atherosclerotic human arteries.","volume":"89","author":"Schneiderman","year":"1992","journal-title":"Proc Natl Acad Sci USA"},{"key":"2020071619403596600_R9","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1055\/s-0038-1648809","article-title":"Plasminogen activator inhibitor-1 expression in human liver and healthy or atherosclerotic vessel walls.","volume":"72","author":"Chomiki","year":"1994","journal-title":"Thromb Haemost"},{"key":"2020071619403596600_R10","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1056\/NEJM198512193132501","article-title":"Increased plasma levels of a rapid inhibitor of tissue plasminogen activator in young survivors of myocardial infarction.","volume":"313","author":"Hamsten","year":"1985","journal-title":"N Engl J Med"},{"key":"2020071619403596600_R11","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S0140-6736(87)93050-9","article-title":"Plasminogen activator inhibitor in plasma: risk factor for recurrent myocardial infarction.","volume":"2","author":"Hamsten","year":"1987","journal-title":"Lancet"},{"key":"2020071619403596600_R12","doi-asserted-by":"crossref","first-page":"2380","DOI":"10.1161\/01.CIR.95.10.2380","article-title":"Fibrinolytic variables and cardiovascular prognosis in patients with stable angina pectoris treated with verapamil or metoprolol. Results from the Angina Prognosis study in Stockholm.","volume":"95","author":"Held","year":"1997","journal-title":"Circulation"},{"key":"2020071619403596600_R13","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1016\/0955-0674(89)90068-9","article-title":"Proteinases and extracellular matrix remodeling.","volume":"1","author":"Alexander","year":"1989","journal-title":"Curr Opin Cell Biol"},{"key":"2020071619403596600_R14","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1172\/JCI118396","article-title":"Bleomycin-induced pulmonary fibrosis in transgenic mice that either lack or overexpress the murine plasminogen activator inhibitor-1 gene.","volume":"97","author":"Eitzman","year":"1996","journal-title":"J Clin Invest"},{"key":"2020071619403596600_R15","doi-asserted-by":"crossref","first-page":"1969","DOI":"10.1161\/01.CIR.87.6.1969","article-title":"Stimulation of plasminogen activator inhibitor in vivo by infusion of angiotensin II.","volume":"87","author":"Ridker","year":"1993","journal-title":"Circulation"},{"key":"2020071619403596600_R16","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1161\/01.HYP.32.6.965","article-title":"Effect of activation and inhibition of the renin angiotensin system on plasma PAI-1 in humans.","volume":"329","author":"Brown","year":"1998","journal-title":"Hypertension"},{"key":"2020071619403596600_R17","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/S0895-7061(97)91128-6","article-title":"Effect of trandolapril and losartan on plasma PAI-1 and fibrinogen in hypertensive post-menopausal women.","volume":"11","author":"Mugellini","year":"1998","journal-title":"Am J Hypertens"},{"key":"2020071619403596600_R18","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1161\/01.CIR.96.2.442","article-title":"Effects of ramipril on plasma fibrinolytic balance in patients with acute anterior myocardial infarction.","volume":"96","author":"Vaughan","year":"1997","journal-title":"Circulation"},{"key":"2020071619403596600_R19"},{"key":"2020071619403596600_R20","doi-asserted-by":"crossref","first-page":"5525","DOI":"10.1073\/pnas.85.15.5525","article-title":"Type 1 plasminogen activator inhibitor gene: functional analysis and glucocorticoid regulation of its promoter.","volume":"85","author":"Zonneveld","year":"1988","journal-title":"Proc Natl Acad Sci USA"},{"key":"2020071619403596600_R21","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1006\/cimm.1993.1263","article-title":"Regulation of plasminogen activator inhibitor-1 levels in human monocytes.","volume":"152","author":"Hamilton","year":"1993","journal-title":"Cell Immunol"},{"key":"2020071619403596600_R22","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1210\/mend-3-1-185","article-title":"Glucocorticoid and cyclic nucleotide regulation of plasminogen activator and plasminogen activator-inhibitor gene expression in primary cultures of rat hepatocytes.","volume":"3","author":"Heaton","year":"1989","journal-title":"Mol Endocrinol"},{"key":"2020071619403596600_R23","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1111\/j.1749-6632.1981.tb29767.x","article-title":"Human fibroblasts produce inhibitor directed against plasminogen activator when treated with glucocorticoids.","volume":"370","author":"Crutchley","year":"1981","journal-title":"Ann NY Acad Sci"},{"key":"2020071619403596600_R24","doi-asserted-by":"crossref","first-page":"3021","DOI":"10.1128\/MCB.7.8.3021","article-title":"Plasminogen activator inhibitor type 1 biosynthesis and mRNA level are increased by dexamethasone in human fibrosarcoma cells.","volume":"7","author":"Andreasen","year":"1987","journal-title":"Mol Cell Biol"},{"key":"2020071619403596600_R25","first-page":"364","article-title":"Glucocorticoid modulation of plasminogen activators and of one of their inhibitors in the human mammary carcinoma cell line MDA-MB-231.","volume":"47","author":"Busso","year":"1987","journal-title":"Cancer Res"},{"key":"2020071619403596600_R26","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1055\/s-0038-1661436","article-title":"The dexamethasone-induced inhibitor of plasminogen activator in hepatoma cells is antigenically-related to an inhibitor produced y bovine aortic endothelial cells.","volume":"55","author":"Loskutoff","year":"1986","journal-title":"Thromb Haemost"},{"key":"2020071619403596600_R27","doi-asserted-by":"crossref","first-page":"6847","DOI":"10.1016\/S0021-9258(17)39805-8","article-title":"Dexamethasone induction of an inhibitor of plasminogen activator in HTC hepatoma cells.","volume":"259","author":"Cwikel","year":"1984","journal-title":"J Biol Chem"},{"key":"2020071619403596600_R28","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1161\/01.HYP.13.6.706","article-title":"Angiotensin II induces c-fos expression in smooth muscle via transcriptional control.","volume":"13","author":"Naftilan","year":"1989","journal-title":"Hypertension"},{"key":"2020071619403596600_R29","first-page":"1","volume":"3","journal-title":"Prog Hemostasis Thromb"},{"key":"2020071619403596600_R30","doi-asserted-by":"crossref","first-page":"8225","DOI":"10.1074\/jbc.273.14.8225","article-title":"Sp1 sites mediate activation of the plasminogen activator inhibitor-1 promoter by glucose in vascular smooth muscle cells.","volume":"273","author":"Chen","year":"1998","journal-title":"J Biol Chem"},{"key":"2020071619403596600_R31","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1161\/01.HYP.27.6.1224","article-title":"Multiple enhancer elements mediate induction of c-fos in vascular smooth muscle cells.","volume":"27","author":"Chen","year":"1996","journal-title":"Hypertension"},{"key":"2020071619403596600_R32","author":"Sambrook","year":"1989"},{"key":"2020071619403596600_R33","first-page":"847","article-title":"Circulating levels of angiotensin I measured by radioimmunoassay in hypertensive subjects.","volume":"93","author":"Workman","year":"1979","journal-title":"J Lab Clin Med"},{"key":"2020071619403596600_R34","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/0008-6363(96)00053-3","article-title":"Potentiation of angiotensin II action by corticosteroids in vascular tissue.","volume":"32","author":"Ullian","year":"1996","journal-title":"Cardiovasc Res"},{"key":"2020071619403596600_R35","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1161\/01.HYP.20.1.67","article-title":"Aldosterone enhances angiotensin II receptor binding and inositol phosphate responses.","volume":"20","author":"Ullian","year":"1992","journal-title":"Hypertension"},{"key":"2020071619403596600_R36","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1161\/01.CIR.90.1.362","article-title":"Angiotensin II increases plasminogen activator inhibitor type 1 and tissue-type plasminogen activator messenger RNA in cultured rat aortic smooth muscle cells.","volume":"90","author":"Leeuwen","year":"1994","journal-title":"Circulation"},{"key":"2020071619403596600_R37","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1126\/science.3037703","article-title":"Cloning of human mineralocorticoid receptor complementary DNA: structural and functional kinship with the glucocorticoid receptor.","volume":"237","author":"Arriza","year":"1987","journal-title":"Science"},{"key":"2020071619403596600_R38","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1080\/07435808909039097","article-title":"Mechanisms of action of mineralocorticoid hormones.","volume":"15","year":"1989","journal-title":"Endocr Res"},{"key":"2020071619403596600_R39","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1161\/01.HYP.31.1.459","article-title":"Localization of 2\u03b2-OH steroid dehydrogenase isoforms in aortic endothelial cells.","volume":"31","author":"Brem","year":"1998","journal-title":"Hypertension"},{"key":"2020071619403596600_R40","first-page":"E900","article-title":"Substrate and inhibitor specificity of the cloned human 11\u03b2-hydroxysteroid dehydrogenase type 2 isoform","volume":"270","author":"Ferrari","year":"1996","journal-title":"Am J Physiol."},{"key":"2020071619403596600_R41","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1161\/01.RES.76.6.973","article-title":"Nongenomic effects of aldosterone on intracellular Ca2+ in vascular smooth muscle cells.","volume":"76","author":"Wehling","year":"1995","journal-title":"Circ Res"},{"key":"2020071619403596600_R42","first-page":"I","article-title":"Angiotensin II and angiotensin IV induce PAI-1 expression through a shared promoter element","volume":"98","author":"Eren","year":"1998","journal-title":"Circulation."},{"key":"2020071619403596600_R43","doi-asserted-by":"crossref","first-page":"1822","DOI":"10.1161\/01.ATV.13.12.1822","article-title":"Augmentation of synthesis of plasminogen activator inhibitor type-1 in arterial endothelial cells by glucose and its implications for local fibrinolysis.","volume":"13","author":"Nordt","year":"1993","journal-title":"Arterioscler Thromb"},{"key":"2020071619403596600_R44","first-page":"9959","volume":"88","author":"Schneider","year":"1991","journal-title":"Augmentation of synthesis of plasminogen activator inhibitor type 1 by insulin and insulin-like growth factor type I: implications for vascular disease in hyperinsulinemic states Proc Natl Acad Sci USA"},{"key":"2020071619403596600_R45","first-page":"411","article-title":"Evidence for a renin receptor on human mesangial cells: effects on PAI-1 and cGMP.","volume":"19","author":"Nguyen","year":"1998","journal-title":"Nephrologie"},{"key":"2020071619403596600_R46","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1016\/0735-1097(92)90596-F","article-title":"Fibrinolytic response during exercise and epinephrine infusion in the same subjects.","volume":"19","author":"Chandler","year":"1992","journal-title":"J Am Coll Cardiol"},{"key":"2020071619403596600_R47","first-page":"244","volume":"18","author":"Mustonen","year":"1998","journal-title":"Physical exertion induces thrombin formation and fibrin degradation in patients with peripheral atherosclerosis Arterioscler Thromb"},{"key":"2020071619403596600_R48","first-page":"893","article-title":"Mineralocorticoid excess, dietary sodium, and myocardial fibrosis.","volume":"120","author":"Brilla","year":"1992","journal-title":"J Lab Clin Med"},{"key":"2020071619403596600_R49","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1161\/01.ATV.17.6.1152","article-title":"Prevention of aortic fibrosis by pironolactone in spontaneously hypertensive rats.","volume":"17","author":"Benetos","year":"1997","journal-title":"Arterioscler ThrombVasc Biol"},{"key":"2020071619403596600_R50","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1172\/JCI118867","article-title":"Role of aldosterone in the remnant kidney model in the rat.","volume":"98","author":"Greene","year":"1996","journal-title":"J Clin Invest"},{"key":"2020071619403596600_R51","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1161\/01.HYP.21.6.929","article-title":"Vasodilation to acetylcholine in primary and secondary forms of human hypertension.","volume":"21","author":"Taddei","year":"1993","journal-title":"Hypertension"},{"key":"2020071619403596600_R52","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/0039-128X(94)00026-9","article-title":"Aldosterone biosynthesis and action in vascular cells.","volume":"60","author":"Takeda","year":"1995","journal-title":"Steroids"},{"key":"2020071619403596600_R53","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1161\/01.HYP.25.1.30","article-title":"Relationships among plasma aldosterone, high-density lipoprotein cholesterol, and insulin in humans.","volume":"25","author":"Goodfriend","year":"1995","journal-title":"Hypertension"},{"key":"2020071619403596600_R54","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1055\/s-0038-1657607","article-title":"PAI-1, obesity, insulin resistance and risk of cardiovascular events.","volume":"78","author":"Juhan-Vague","year":"1997","journal-title":"Thromb Haemost"},{"key":"2020071619403596600_R55","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1007\/BF00877755","article-title":"\u201cEscape\u201d of aldosterone production in patients with left ventricular dysfunction treated with an angiotensin converting enzyme inhibitor: implications for therapy.","volume":"9","year":"1995","journal-title":"Cardiovasc Drugs Ther"},{"key":"2020071619403596600_R56","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJM199909023411001","article-title":"The effect of spironolactone on morbidity and mortality in patients with severe heart failure.","volume":"341","author":"Pitt","year":"1999","journal-title":"N Engl J Med"}],"container-title":["The Journal of Clinical Endocrinology &amp; Metabolism"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jcem\/article-pdf\/85\/1\/336\/9186145\/jcem0336.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/jcem\/article-pdf\/85\/1\/336\/9186145\/jcem0336.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,22]],"date-time":"2022-03-22T00:03:07Z","timestamp":1647907387000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcem\/article\/85\/1\/336\/2855853"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2000,1,1]]},"references-count":56,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2000,1,1]]}},"URL":"https:\/\/doi.org\/10.1210\/jcem.85.1.6305","relation":{},"ISSN":["0021-972X","1945-7197"],"issn-type":[{"value":"0021-972X","type":"print"},{"value":"1945-7197","type":"electronic"}],"subject":[],"published":{"date-parts":[[2000,1,1]]}}}